Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aprepitant versus ondansetron for prevention of postoperative vomiting
2006-001761-42Phase 3Terminated
- Sponsor
- Merck & Co.
- Start
- Apr 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of aprepitant in postoperative nausea and vomiting (PONV) (2 arms), sponsored by Merck & Co. Primary endpoints: No Vomiting 0–24 hours and No Vomiting 0–48 hours. Started Apr 2006; status: terminated.
02
Drugs
aprepitant
03
Conditions
postoperative nausea and vomiting (PONV)
Beyond the preview
Go deeper on 2006-001761-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-001761-42.